Articles by Editor

There is a quote that has been attributed loosely to Ernest Hemingway that I find very useful in teaching my two daughters.
My preferred version of it is this:
When asked how he went bankrupt, the man replied, “Slowly, and then all at once.”
The point is that you can get away with something for a really, really long time.
And then, all of a sudden, you find yourself paying a price so dear you can’t believe how stupid you were.
I’m thinking of this quote today for a specific reason.
Because generally speaking, if you print a lot of money, you get inflation.
Well, let …read more […]

This just might be the greatest Trade Talk Tuesdays I’ve ever recorded…
It’s a special “alternative investments” episode…
Which reveals a “secret” sports card that just sold on eBay for more than $38,000!
And guess what?
If you’ve ever set foot inside a grocery store, you just might have this card in your house – right now.
Do you have it?
There’s only one way to find out…
Watch my newest Trade Talk Tuesdays alternative investments episode right now!
Just click the link below!

For more insight on investment opportunities, trading strategies and more… join me in The War Room!
The post Sports Card Investing: This $38,000 Card Might Be …read more […]

To say Seres Therapeutics (MCRB) began the week with a bang would be a severe understatement. More like an earth-shattering explosion. Shares surged by 390% in Monday’s trading after the microbiome drug maker announced positive results from a clinical trial.In a Phase 3 study of SER-109 for the treatment of recurrent C. difficile infection (CDI), the oral microbiome medicine exhibited a 30.2% drop in the proportion of patients who experienced a recurrence in CDI within an eight week period compared to placebo. Overall, only 11.1% of patients given the treatment experienced a CDI recurrence as opposed to 41.3% in the …read more […]

(Bloomberg) — Tesla Inc. is splitting its elevated shares in a 5-for-1 exchange, a move timed to make the stock less expensive for individual investors after the company become the world’s most valuable automaker. Its shares surged on the news in aftermarket trading.Each shareholder of record on Aug. 21 will receive a dividend of four additional shares of common stock for each share, the Silicon Valley electric-car manufacturer said Tuesday. Trading will begin on a split-adjusted basis on Aug. 31.The split is a timely decision to capitalize on Tesla’s recent surge, which has pushed its valuation to around $256 billion, …read more […]

Stocks opened higher Tuesday evening, after a choppy session earlier sent the S&P 500 within striking distance of a record close before the the blue-chip index lost steam and declined. …read more […]

(Bloomberg) — The rally that pushed gold to record heights above $2,000 an ounce has come to an abrupt halt, with the haven metal posting the biggest drop in seven years after bond yields spiked higher.Treasury bond yields climbed, cutting into the negative real rates that had supported the metal. The 10-year Treasury yield jumped the most since June ahead of an expected flood of government and corporate debt issuance. U.S. producer prices increased faster than expected.“Today real rates clearly moved higher and that’s clearly what moved gold lower,” Michael Widmer, head of metals research at Bank of America Merrill …read more […]

There’s a new FDA-approved pain medication on the scene. On Monday, Trevena (TRVN) announced that Olinvyk (oliceridine), the company’s opioid agonist, finally received the FDA’s nod of approval for the management of acute pain in adults who need an intravenous opioid pain reliever. The drug is to be administered in hospitals or other controlled clinical settings.The approval brings to an end a process stretching back to 2018, when Trevena received the dreaded complete response letter (CRL) from the FDA, citing concerns regarding the size of the safety database and potential for QT prolongation.H.C. Wainwright analyst Douglas Tsao calls the approval …read more […]

Trends Expert Matthew Carr examines the global internet of things security market and its future growth potential.
There’s a special class of companies I like to target called “20/20 small caps.”
And I can’t imagine a more apt year to talk about them than 2020.
These are companies that are seeing at least 20% revenue growth and 20% earnings growth. Over the years, I’ve found that these are some of the most profitable stocks to invest in.
Today, I want to highlight a company that’s a 20/20 small cap. But it’s also involved in an opportunity that often gets overlooked by investors.
Internet of Things: …read more […]

…read more […]

Invesco Global Market Strategist Brian Levitt joins Yahoo Finance’s Kristin Myers to discuss his market outlook amid hopes for a vaccine and further stimulus.
…read more […]

Joe Biden used a tax strategy to evade paying hundreds of thousands of dollars in payroll taxes, as he criticizes President Trump’s plan for a payroll tax deferral. …read more […]

Stocks fell Tuesday, with the S&P 500 closing in on a record level earlier in the session as hopes for a vaccine and further stimulus spurred a global risk rally and a pop in “reopening” stocks. The Nasdaq underperformed again, with some major tech names that had recently led the market higher giving back some gains. …read more […]

…read more […]

(Bloomberg) — Tesla Inc. says hedge fund Cable Car Capital LLC, which is shorting the company’s stock, is funding a former employee’s defamation allegations.The carmaker said in a filing Monday that Martin Tripp’s counterclaim against Tesla was being funded by Cable Car, even though Tripp has said under oath that he had no financing or connection to Tesla short sellers.Cable Car portfolio manager Jacob Ma-Weaver had no immediate comment.Tesla sought an emergency order from a judge forbidding Tripp from publicizing confidential information. Tripp has disclosed volumes of Tesla’s confidential documents, deposition transcripts and filings in his posts on Twitter, YouTube …read more […]

Both Inovio and BionNTech announced that they are making headway in their coronavirus vaccine trials, and will be able to meet deadlines toward the end of the year or a the start of 2021. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round. …read more […]